Quantifying EU Medicine Access Challenges

By Rene Pretorius

June 6, 2025

Introduction

While EU medicine access challenges are a widely acknowledged reality, the 2024 EFPIA Patients W.A.I.T. Indicator study and Charles River Associates report quantify these hurdles, revealing a shared burden for industry and patients across Europe. With only 46% of centrally approved medicines (2020–2023) available in 2024, down from 48% in 2019, and public reimbursement rates dropping to 29% from 42%, these reports highlight systemic inequities. This summary distills the foremost EU medicine access challenges to guide strategic planning and advocate for policy reforms that enhance market entry and patient outcomes.

Main Findings

EU Medicine Access Challenges: Growing Delays

  • 578 days: Average time to market availability in 2024, up from 531 days in 2023, a 47-day increase.

  • Country disparities: Germany achieves access in 128 days, while Portugal requires 840 days.

  • Two-thirds of delays stem from regulatory bottlenecks, health technology assessments, and reimbursement negotiations. Executives must prioritize early payer engagement to mitigate these delays.

Limited Availability and Restricted Access

  • 46% availability: Only 46% of innovative medicines approved centrally (2020–2023) were available in 2024, with disparities favoring Northern/Western Europe.

  • 17% restricted access: Medicines with reimbursement restrictions rose from 6% in 2019 to 17% in 2024; reimbursement rates fell to 29%.

  • Smaller markets face structural barriers, limiting access to advanced therapies. Tailored evidence packages are critical to navigate restrictive reimbursement systems.

EU Medicine Access Challenges: Infrastructure and Policy

  • Key barriers: Insufficient diagnostic capacity, staff specialization, duplicate evidence requests, and non-harmonized pricing frameworks hinder access.

  • Policy risks: Proposed EU legislation weakening IP protections and external reference pricing could divert R&D to the U.S./China. Executives should advocate for policy reforms and invest in market-specific solutions.

Strategic Priorities for Market Access

  • EU HTA Regulation (Jan 2025): Mandates joint clinical assessments, requiring early HTA engagement.

  • EFPIA proposals: Equity-based tiered pricing and outcomes-based payment models can accelerate access, alongside the EU Critical Medicines Act.

  • WHO/Europe Platform: Partnerships with smaller markets can reduce disparities. Executives must allocate resources for robust HTA submissions to overcome EU medicine access challenges.

Conclusion

The EFPIA report underscores access challenges in Europe, with 578-day delays, 46% availability, and 17% restricted access signaling systemic issues harming outcomes, especially for cancer treatments. Executives should focus on early HTA engagement, tailored reimbursement strategies, equity-based pricing, and policy advocacy, including tailored approaches for smaller markets, to ensure timely launches and equitable access, strengthening their EU market position.

Reference url

Recent Posts

prior authorization reforms
     

Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?

The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.

Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.